山东大学耳鼻喉眼学报 ›› 2019, Vol. 33 ›› Issue (3): 42-48.doi: 10.6040/j.issn.1673-3770.1.2019.001
摘要:
以铂类为基础的化疗联合西妥昔单抗是复发或转移性头颈鳞状细胞癌(R/M HNSCC)的标准治疗方式,然而治疗后有易复发、中位生存期短等问题。以PD-1/PDL-1单抗为主的免疫检查点抑制剂(ICIs)开始成为R/M HNSCC新的临床治疗方案,且pembrolizumab和nivolumab都已被FDA批准用于经铂类治疗失败的R/M HNSCC。现就ICIs在R/M HNSCC的临床试验进行系统汇总,并对药物的不良反应及生物标志物进行阐述,为未来在R/M HNSCC中使用ICIs提供理论基础。
中图分类号:
1 |
SiegelRL, MillerKD, JemalA. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. doi:10.3322/caac.21254.
doi: 10.3322/caac.21254 |
2 |
ChenWQ, ZhengRS, BaadePD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi:10.3322/caac.21338.
doi: 10.3322/caac.21338 |
3 |
SaccoAG, CohenEE. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma[J]. JCO, 2015, 33(29): 3305-3313. doi:10.1200/jco.2015.62.0963.
doi: 10.1200/jco.2015.62.0963 |
4 |
SeiwertTY, BurtnessB, MehraR, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7): 956-965. doi:10.1016/S1470-2045(16)30066-3.
doi: 10.1016/S1470-2045(16)30066-3 |
5 |
FerrisRL, BlumenscheinG Jr, FayetteJ, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19): 1856-1867. doi:10.1056/nejmoa1602252.
doi: 10.1056/nejmoa1602252 |
6 |
MeleroI, GaudernackG, GerritsenW, et al. Therapeutic vaccines for cancer: an overview of clinical trials[J]. Nat Rev Clin Oncol, 2014, 11(9): 509-524. doi:10.1038/nrclinonc.2014.111.
doi: 10.1038/nrclinonc.2014.111 |
7 |
MahoneyKM, RennertPD, FreemanGJ. Combination cancer immunotherapy and new immunomodulatory targets[J]. Nat Rev Drug Discov, 2015, 14(8): 561-584. doi:10.1038/nrd4591.
doi: 10.1038/nrd4591 |
8 |
BrahmerJR, TykodiSS, ChowLQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26): 2455-2465. doi:10.1056/NEJMoa1200694.
doi: 10.1056/NEJMoa1200694 |
9 |
MoyJD, MoskovitzJM, FerrisRL. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma[J]. Eur J Cancer, 2017, 76: 152-166. doi:10.1016/j.ejca. 2016.12.035.
doi: 10.1016/j.ejca. 2016.12.035 |
10 |
HannaGJ, LiuHY, JonesRE, et al. Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck[J]. Oral Oncol, 2017, 67: 61-69. doi:10.1016/j.oraloncology. 2017.02.005.
doi: 10.1016/j.oraloncology. 2017.02.005 |
11 |
TongCC, KaoJ, SikoraAG. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer[J]. Immunol Res, 2012, 54(1/2/3): 266-274. doi:10.1007/s12026-012-8306-6.
doi: 10.1007/s12026-012-8306-6 |
12 |
MattoxAK, LeeJ, WestraWH, et al. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4+ TILs in the presence of PD-l1+ TAMs[J]. Cancer Res, 2017, 77(22): 6365-6374. doi:10.1158/0008-5472.CAN-16-3453.
doi: 10.1158/0008-5472.CAN-16-3453 |
13 |
ZhaoMY, LiY, WeiX, et al. Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma[J]. Virol J, 2017, 14(1): 5. doi:10.1186/s12985-016-0670-8.
doi: 10.1186/s12985-016-0670-8 |
14 |
MandalR, ŞenbabaoğluY, DesrichardA, et al. The head and neck cancer immune landscape and its immunotherapeutic implications[J]. JCI Insight, 2016, 1(17): e89829. doi:10.1172/jci.insight.89829.
doi: 10.1172/jci.insight.89829 |
15 |
OoftML, van IpenburgJA, SandersME, et al. Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma[J]. J Clin Pathol, 2018, 71(3): 267-274. doi:10.1136/jclinpath-2017-204664.
doi: 10.1136/jclinpath-2017-204664 |
16 |
ChowLQM, HaddadR, GuptaS, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase ib KEYNOTE-012 expansion cohort[J]. JCO, 2016, 34(32): 3838-3845. doi:10.1200/jco.2016.68.1478.
doi: 10.1200/jco.2016.68.1478 |
17 |
BaumlJ, SeiwertTY, PfisterDG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study[J]. J Clin Oncol, 2017, 35(14): 1542-1549. doi:10.1200/JCO.2016.70.1524.
doi: 10.1200/JCO.2016.70.1524 |
18 |
CohenEE, HarringtonKJ, Le TourneauC, et al. LBA45PRPembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial[J]. Annals of Oncology, 2017, 28(suppl_5):v605-v649. doi:10.1093/annonc/mdx440.040.
doi: 10.1093/annonc/mdx440.040 |
19 |
SzturzP, VermorkenJB. Immunotherapy in head and neck cancer: aiming at EXTREME precision[J]. BMC Med, 2017, 15(1): 110. doi:10.1186/s12916-017-0879-4.
doi: 10.1186/s12916-017-0879-4 |
20 |
WolchokJD, RollinL, LarkinJ. Nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2017, 377(25): 2503-2504. doi:10.1056/NEJMc1714339.
doi: 10.1056/NEJMc1714339 |
21 |
MotzerRJ, TannirNM, McDermottDF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290. doi:10.1056/NEJMoa1712126.
doi: 10.1056/NEJMoa1712126 |
22 |
JiangT, ZhouCC. The past, present and future of immunotherapy against tumor[J]. Transl Lung Cancer Res, 2015, 4(3): 253-264. doi:10.3978/j.issn.2218-6751.2015.01.06.
doi: 10.3978/j.issn.2218-6751.2015.01.06 |
23 |
LeDT, DurhamJN, SmithKN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349): 409-413. doi:10.1126/science.aan6733.
doi: 10.1126/science.aan6733 |
24 |
AguiarPN Jr, De MelloRA, HallP, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data[J]. Immunotherapy, 2017, 9(6): 499-506. doi:10.2217/imt-2016- 0150.
doi: 10.2217/imt-2016- 0150 |
25 |
KaramouzisMV, PapavassiliouAG. Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect-a glimpse to the future[J]. Expert Opin Investig Drugs, 2018, 27(7): 569-572. doi: 10.1080/13543784.2018.1494724.
doi: 10.1080/13543784.2018.1494724 |
26 |
GandhiL, Rodríguez-AbreuD, GadgeelS, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092. doi:10.1056/NEJMoa1801005.
doi: 10.1056/NEJMoa1801005 |
27 |
WolchokJD, Chiarion-SileniV, GonzalezR, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2017, 377(14): 1345-1356. doi:10.1056/NEJMoa1709684.
doi: 10.1056/NEJMoa1709684 |
28 |
OvermanMJ, LonardiS, WongKYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-Deficient/Microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779. doi:10.1200/JCO.2017.76.9901.
doi: 10.1200/JCO.2017.76.9901 |
29 |
BuruguS, DancsokAR, NielsenTO. Emerging targets in cancer immunotherapy[J]. Semin Cancer Biol, 2018, 52(Pt 2): 39-52. doi:10.1016/j.semcancer. 2017.10.001.
doi: 10.1016/j.semcancer. 2017.10.001 |
30 |
BeattyGL, LiY, LongKB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists[J]. Expert Rev Anticancer Ther, 2017, 17(2): 175-186. doi:10.1080/14737140.2017.1270208.
doi: 10.1080/14737140.2017.1270208 |
31 |
HowardA. Burris, Jeffrey R. Infante, Stephen Maxted Ansell,et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors [J]. JCO, 2017, 35(18): 2028-2036.doi: 10.1200/JCO.2016.70.1508.
doi: 10.1200/JCO.2016.70.1508 |
32 |
邱春燕,张火俊. 新兴免疫检查点靶点的研究进展[J]. 中国肿瘤生物治疗杂志, 2018, 25(7):733-736.doi:10.3872/j.issn.1007-385x.2018.07.013.
doi: 10.3872/j.issn.1007-385x.2018.07.013 |
[1] | 刘坤, 张欣欣. 循环肿瘤细胞在头颈部鳞癌中的富集及检测[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 18-24. |
[2] | 沈宇杰,张立庆,周涵,赵青,冯剑,宋圣花,董伟达. 颈部脂肪瘤34例临床分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 111-115. |
[3] | 陈慧君,宋圣花,周涵,董伟达,乔明哲,陈曦,徐进,林子萍,邢光前. 血小板与淋巴细胞比值对喉癌复发的预测价值[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 106-110. |
[4] | 胡娟娟, 洪育明. 咽旁间隙肿瘤的诊断和治疗[J]. 山东大学耳鼻喉眼学报, 2014, 28(5): 85-90. |
[5] | 叶萍,孙睿杰,金童,钱晔,魏东敏,潘新良. Caveolin-1在下咽鳞癌中的表达及其临床意义[J]. 山东大学耳鼻喉眼学报, 2012, 26(5): 22-24. |
[6] | 甘卫刚1综述, 洪育明2审校. 整合素β1与头颈部肿瘤关系的研究进展[J]. 山东大学耳鼻喉眼学报, 2011, 25(1): 31-34. |
[7] | 吕佳宝综述,邱连升审校. p27kip1、Skp2与头颈部肿瘤关系的研究进展[J]. 山东大学耳鼻喉眼学报, 2009, 23(5): 17-20. |
[8] | 黄 方,朱从月 . p21、p73及PTEN在头颈部多原发癌中的表达及意义[J]. 山东大学耳鼻喉眼学报, 2007, 21(5): 388-392 . |
[9] | 鞠秀婷,夏 明 综述, 解 光 审校 . CD4+CD25+调节性T细胞与头颈部肿瘤局部免疫抑制的关系[J]. 山东大学耳鼻喉眼学报, 2007, 21(2): 177-180 . |
[10] | 宋西成,张华,张庆泉 . 血循环DNA的检测与头颈部肿瘤的诊断[J]. 山东大学耳鼻喉眼学报, 2006, 20(5): 385-387 . |
[11] | 朱从月,黄方 . p21、p73和PTEN蛋白表达联合检测在头颈部多原发癌诊断中的价值[J]. 山东大学耳鼻喉眼学报, 2006, 20(4): 352-354 . |
[12] | 朱从月,杨劲松,黄方 . G1细胞周期调控与头颈部多原发癌的关系[J]. 山东大学耳鼻喉眼学报, 2006, 20(3): 268-271 . |
[13] | 林海,甄泽年,赵敏,袁友文,杨甫文 . 咽旁间隙肿瘤手术路径探讨(附46例分析)[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 63-64 . |
|